InnovAge Holding Corp. INNV
InnovAge is the leading healthcare delivery platform by number of participants focused on providing all-inclusive, capitated care to high-cost, seniors, many of whom are dual-eligible. Our programs are designed to address two of the most pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of our participant-centered care delivery approach is to improve the quality of care our participants receive, while keeping them in their homes for as long as safely possible and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. Through our Program of All-Inclusive Care for the Elderly ("PACE"), we fulfill a broad range of medical and ancillary services for seniors, including in-home care services (skilled, unskilled and personal care), in-center services such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center and third-party medical appointments; and care management. We directly contract with government payors, such as Medicare and Medicaid, and do not rely on third-party administrative organizations or health plans. We believe our model aligns with how healthcare is evolving, namely (i) the shift toward value-based care, in which coordinated, outcomes-driven, quality care is delivered while reducing unnecessary spend, (ii) eliminating excessive administrative costs by contracting directly with the government, (iii) focusing on the patient experience, and (iv) addressing social determinants of health.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $853.7M | $763.9M | $688.1M | $698.6M | $637.8M | $567.2M | — | — |
| Gross profit | $153.6M | $132.1M | $101.3M | $135.4M | — | — | — | — |
| SG&A | $122.1M | $111.3M | $115.6M | $101.7M | $132.3M | $58.5M | — | — |
| Total operating expenses | $883.5M | $787.0M | $737.5M | $703.0M | $650.1M | $516.3M | — | — |
| Operating income | -$29.8M | -$23.2M | -$49.4M | -$4.4M | -$12.3M | $50.9M | — | — |
| Interest expense | — | — | — | $2.5M | $16.8M | $14.6M | — | — |
| Pre-tax income | -$29.0M | -$19.9M | -$33.4M | -$5.8M | -$34.2M | $36.1M | — | — |
| Income tax | $1.3M | $1.4M | $7.2M | $723.0K | $9.8M | $9.9M | — | — |
| Net income | -$30.3M | -$21.3M | -$40.7M | -$6.5M | -$44.0M | $26.3M | — | — |
| EPS, basic | -0.22 | -0.16 | -0.30 | -0.05 | -0.36 | 0.20 | — | — |
| EPS, diluted | -0.22 | -0.16 | -0.30 | -0.05 | -0.36 | 0.19 | — | — |
| Shares, diluted (wtd. avg.) | $135.4M | $135.9M | $135.6M | $135.5M | $123.6M | $135.2M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $64.1M | $56.9M | $127.3M | $184.4M | $203.7M | $114.6M | $61.2M | $9.0M |
| Short-term investments | $41.8M | $45.8M | $46.2M | $0 | — | — | — | — |
| Receivables | $36.4M | $48.1M | $24.3M | $35.9M | $32.6M | $46.3M | — | — |
| Total current assets | $176.1M | $173.1M | $215.2M | $241.0M | $250.9M | $166.9M | — | — |
| Property, plant and equipment | — | — | — | $176.3M | $142.7M | $102.5M | — | — |
| Goodwill | $142.0M | $139.9M | $124.2M | $124.2M | $124.2M | $116.1M | $117.3M | — |
| Other intangibles | $3.9M | $4.5M | $5.2M | $5.9M | $6.5M | $5.2M | — | — |
| Total assets | $526.9M | $547.7M | $567.4M | $555.6M | $531.8M | $409.6M | — | — |
| Accounts payable | $76.8M | $55.5M | $54.9M | $50.6M | $32.4M | $28.9M | — | — |
| Short-term debt | $2.2M | $3.8M | $3.8M | $3.8M | $3.8M | $1.9M | — | — |
| Total current liabilities | $164.8M | $138.6M | $148.4M | $105.3M | $78.6M | $76.6M | — | — |
| Long-term debt | $57.5M | $61.5M | $64.8M | $68.2M | $71.6M | $210.4M | — | — |
| Total liabilities | $263.9M | $247.9M | $252.6M | $201.9M | $173.8M | $301.9M | — | — |
| Retained earnings | -$101.0M | -$68.3M | -$35.9M | $4.7M | $10.7M | $64.7M | — | — |
| Total equity | $235.0M | $269.3M | $302.1M | $338.5M | $341.0M | $107.8M | $81.4M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $32.9M | -$36.9M | $20.2M | $27.3M | -$7.5M | $43.8M | — | — |
| Depreciation and amortisation | $19.5M | $18.9M | $15.4M | $13.9M | $12.3M | $11.3M | — | — |
| Stock-based compensation | $7.6M | $6.8M | $4.6M | $3.7M | $1.7M | $543.0K | — | — |
| Capital expenditure | $6.3M | $7.9M | $23.4M | $38.2M | $17.5M | $11.8M | — | — |
| Investing cash flow | -$5.5M | -$26.4M | -$69.5M | -$40.2M | -$19.5M | -$11.7M | — | — |
| Financing cash flow | -$19.1M | -$7.0M | -$7.9M | -$6.3M | $116.2M | $21.2M | — | — |
| Dividends paid | — | — | — | — | $9.5M | — | — | — |
| Buybacks | $7.3M | $179.0K | — | — | $77.6M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001834376-25-000062.
Others in SIC 8000
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LFST | LifeStance Health Group, Inc. | $4.86B | — | 13.9% |
| PRVA | Privia Health Group, Inc. | $2.64B | 114.8x | 22.3% |
| WGS | GeneDx Holdings Corp. | $2.56B | — | 40.0% |
| OMDA | Omada Health, Inc. | $1.39B | — | 53.2% |
| PNTG | Pennant Group, Inc. | $1.33B | 45.2x | 36.3% |
| USPH | U S PHYSICAL THERAPY INC /NV | $1.18B | 55.9x | 16.3% |
| SRTA | Strata Critical Medical, Inc. | $470.6M | 10.6x | 34.3% |
| DCGO | DocGo Inc. | $39.8M | — | -47.7% |